
Oruka's ORKA-001 Sparks Hopes for a Category-Winning Psoriasis Drug
Oruka Therapeutics reports phase 2a results for ORKA-001, a long-acting IL-23 inhibitor for plaque psoriasis, showing 63.5% of treated patients achieving complete skin clearance (40/63) at week 16 versus 1/21 on placebo, with a clean safety profile and potential for annual dosing. Jefferies analysts say the data could outperform Skyrizi and support $5–$10 billion in sales, helping the stock rise about 30% as the company moves to phase 3 with an active comparator.













